Objective To evaluate the impact of using two evidencesynthesis paradigms, pairwise meta-analysis (PMA) vs. network meta-analysis (NMA), on the expected value of information (EVI) outcomes, using pharmacotherapy of chronic obstructive pulmonary disease as a case study. Methods Bayesian random-effects PMAs were performed for each pharmacotherapy vs. placebo, and a Bayesian random-effects NMA was performed combining both placebo-controlled and head-to-head trials. Both provided comparative rate ratio (RR) estimates between each pharmacotherapy vs. placebo. A Markov model was developed to project costs and qualityadjusted life-years of five commonly used treatments for chronic obsructive pulmonary disorder. RRs for the treatment effect compared with placebo derived using PMA and NMA were used alongside values from the literature to populate the model. In addition to standard cost-effectiveness outputs, we calculated and compared the expected value of perfect information (EVPI) and the expected value of partial perfect information (EV-PPI) for treatment effects, for comparisons that included all or a subset of treatments. Results The network of evidence included five different treatments, compared in 19 randomized controlled trials (RCTs), which in total included 28,172 individuals. The cost-effectiveness outcomes were similar between the two evidence-synthesis paradigms. The individual EVPI for all treatments was Can$1,262 for PMA-based analyses and Can$572 for NMA-based analyses. For all comparisons involving two, three, or four treatments, the comparison with the highest EVPI was different between the two methods. Similarly, the choice of PMA or NMA had resulted in substantially different EVPPI rankings. Conclusion Our case study shows that the choice of PMA or NMA can have significant effects on the EVI results. Under comparable conditions, the incorporation of more evidence in the NMA most likely increases the precision of estimates and therefore is likely to result in lower EVI outcomes. As our study demonstrates, the difference in EVI outcomes can be substantial, potentially affecting the decision to conduct research and the design of future research.
Key Points for Decision Makers
The use of network meta-analysis (NMA) instead of pairwise meta-analysis (PMA) for evidence synthesis is becoming popular, but it can be argued that this choice does not result in practical differences for economic evaluations
In a real-world case study, the use of NMA instead of PMA to synthesize evidence on treatment effect substantially affected both the estimate of the benefit of future research and the type of research that should be pursued Recent recommendations on the use of NMAs instead of PMAs for evidence synthesis can have substantial practical implications for economic evaluations, especially in valuing future research
Introduction
Economic evaluation of healthcare technologies is concerned with maximizing measures of health in a target population given a constrained budget. Two key functions of economic evaluations are to inform the 'adoption decision' and the 'research decision' [1, 2] . The adoption decision is concerned with which health technology to adopt given the existing evidence. The research decision tackles the issue of whether more evidence is required to support such an adoption decision. The set of activities informing decisions on future research is often referred to as expected value of information (EVI) analysis [3] . Although the adoption and research decisions can be carried out using a single source of evidence (e.g., economic evaluation alongside a randomized controlled trial [RCT] ), a comprehensive approach often requires decision-analytic modeling and comprehensive evidence synthesis from disparate sources [4, 5] .
A core component of such an economic evaluation is the estimates of treatment effect (e.g., hazard ratio, risk difference, relative risk, odds ratio) among the treatments being evaluated. Such estimates are often generated through evidence synthesis (i.e., meta-analysis) of the RCTs that compare two of the treatments of interest. Traditionally, evidence synthesis is performed on the effect of one treatment vs. another. The evidence generated through such a pairwise meta-analysis (PMA) can be represented by probability distributions for treatment effects between two treatments. Such evidence is then propagated through the decision-analytic model to generate measures of concern for policy making.
When the economic evaluation considers more than two treatments, it is likely that estimates of treatment effect are available from several RCTs of various designs each including a subset of treatments. Together such studies construct a 'network' of comparisons, in that each two treatments (represented by two nodes in the network) are directly and/or indirectly connected. Network meta-analysis (NMA) is the extension of PMA that allows evidence synthesis from studies that each might have compared only a subset of treatments [6] . Evidence on the treatment effect between any two treatments is generated by considering the entire evidence in the network. This provides two key advantages over the more traditional pairwise analyses. First, NMAs can gain precision by 'borrowing strength' from a larger set of RCTs that make up sources of evidence [7] . When the economic evaluation involves more than two strategies, without the use of NMAs, the conventional paradigm is to treat one strategy (e.g., the placebo arm) as the 'reference' and synthesize evidence in a series of PMAs. This practice inevitably ignores studies comparing alternative strategies with each other. Second, the evidence generated through a NMA is always consistent; for example, if the effect size is on the rate ratio (RR) scale, then the RR of treatment A vs. C is the product of the RRs of A vs. B and B vs. C (or similar logical relations for other measures of treatment effect) [8] . This is not necessarily the case if effect sizes are estimated from separate PMAs. Given these, NMAs seem to be the natural choice for evidence synthesis in economic evaluations where more than two interventions are compared.
Of course, the difference in the methodological framework and the data that inform NMA and PMA suggest that the results of both the cost-effectiveness analysis (CEA) and EVI analyses may be affected by the choice of the evidence-synthesis framework. While the impact of NMA ves. PMA on measures of cost effectiveness has received some attention [9, 10] , the impact on EVI outcomes, such as the expected value of perfect information (EVPI), has not hitherto been examined. It is likely that the added precision provided by incorporating the full evidence in NMAs compared with PMAs will result in lower values of EVI metrics. However, to what extent this phenomenon occurs in a real-world setting has not been demonstrated. In this work, we use a case study of pharmacotherapies of chronic obstructive pulmonary disease (COPD) to demonstrate the impact of the evidence synthesis paradigm on the magnitude of EVPI, and the ranking of future RCTs comparing subsets of treatment, based on their EVPIs.
Methods
We built a decision-analytic model to evaluate the CEA of the following five interventions for pharmacotherapy of COPD: no treatment (represented by placebo in the underlying efficacy studies), inhaled corticosteroids (ICS), inhaled long-acting beta agonists (LABA), inhaled longacting muscarinic agents (LAMA), and a combination of ICS ? LABA. We synthesized the evidence from the published RCTs comparing the above-mentioned treatments using both NMA and PMA (placebo comparisons) to generate estimates for the treatment effect. Details of the NMA are provided elsewhere [11] (Please refer to the Online Supplementary Material-Appendix I, for details on the evidence-synthesis models). In summary, all RCTs involving patients with moderate/severe COPD and comparing two or more of the treatments with regard to their effect in reducing the rate of COPD exacerbations were considered. The treatment effect of interest was the RR, compared with placebo, of treatments on the rate of COPD exacerbation. A total of 19 trials (14 two-arm trials, 1 three-arm trial, and 4 four-arm trials) including 28,172 patients constituted the evidence base for treatment effects. Figure 1 provides a schematic illustration of the network of evidence. Most interventions had been compared head-to-head in at least one RCT. RR estimates were obtained using a Bayesian Poisson regression NMA model. Specifically, we followed the published guidelines to perform a random-effects NMA, with non-informative uniform priors between 0 and 2 for the between-study standard deviation, and convergence was ensured by examining whether the trace plots have become stationary [8] . This occurred after 50,000 runs as burn-in. Separately, a Bayesian Poisson regression PMA model was used to obtain conventional pairwise RRs for each of the considered interventions vs. placebo. Both the PMA and NMA models were implemented in WinBUGS [12] . These RRs and their 95 % credible intervals are represented in Table 1 . A consistency table including direct and indirect estimates of RR from PMA and NMA is provided in the Online Supplementary Material Appendix-I.
The COPD Model
We created a discrete time Markov model of COPD to estimate costs, exacerbation rates, and quality-adjusted life-years (QALYs) for each treatment. Costs were reported in year 2011 Canadian dollars ($).The outputs of the model were the discounted 10-year costs, number of exacerbations, and QALYs associated with each treatment. A schematic illustration of the model is provided in Fig. 2 . The model structure is similar to the widely used Burden of Obstructive Lung Disease (BOLD) COPD model [13] . COPD stages were classified as mild (stage I), moderate (stage II), and severe (stage III) according to the Global Initiative for Obstructive Lung Disease (GOLD) criteria [14] . The target population for this study was patients with moderate-to-severe COPD (stages II and III), as studies informing treatment effects only included such patients. Additionally, in our model (as in the BOLD model), transition from a more severe state to a less severe state is impossible. Therefore, the mild state was not implemented in the model as its inclusion would have no practical effect. COPD states were further divided according to the smoking status (current smoker, ex-smoker, and never smoker). The time horizon of the model was 10 years with time cycles of 1 year. Future payoffs were all discounted at 3 %. The model was implemented in the statistical programming environment R v2.14 [15] . Table 1 Includes all parameters and their probability distributions if implemented in the model. All costs are adjusted to Canadian 2011 dollars. C(x, y) denotes the gamma distribution with x as shape parameter and y as rate parameter. B(x, y) denotes the beta distribution with x as shape 1 parameter and y as shape 2 parameter. N(x, y) denotes the normal distribution with x as mean and y as standard deviation COPD chronic obstructive pulmonary disorder, GP general practitioner, ICS inhaled corticosteroids, LABA long-acting beta agonists, LAMA longacting muscarinic agents, NMA network meta-analysis, PMA pairwise meta-analysis a Estimated based on the 10,000 random draws from the posterior distribution from NMA and PMA b Transition rates not presented are all zero. The transition rates across different smoking states are independent of COPD stages c Dirichlet distribution is attributed to each row of the transition matrix d We only assumed probability distributions to their corresponding costs e Exacerbation utilities are modeled over a 3-month period based on Spencer et al. [26] The parameters used to populate the model are presented in Table 1 . The RRs comparing each treatment with placebo were taken from the PMA or NMA, as described above. Other parameters were obtained from a review of the literature (please refer to the Online Supplementary Material-Appendix II for the details on evidence synthesis). All model parameters, except those representing the costs of the study drugs and the RR of treatments, were assigned probability distributions representing the level of uncertainty around the true value of the parameter. The unit cost of study drugs were assumed known and the uncertainty around the RRs were modeled by directly sampling from the posterior distribution of RRs from the PMA or NMA.
Analysis
We ran the model and calculated the model outputs using 10,000 random inputs. We reported the average value of costs, exacerbation rates, and QALYs for each treatment, and calculated the incremental cost-effectiveness ratio (ICER) and the incremental net monetary benefit (INMB, at a willingness-to-pay [WTP] value of Can$50,000/ QALY), compared with placebo, for both PMA-and NMA-based analyses.
The main metric of interest for the present study was the expected value of perfect information (EVPI). EVPI is equal to the opportunity loss because of uncertainty in the underlying evidence [16] . As a secondary outcome, we also calculated the expected value of partial perfect information (EVPPI) associated with treatment effect, which quantifies the opportunity loss because of uncertainty in the treatment effects. Furthermore, we calculated the EVPPI for the costs and utilities. Calculation of EVPPI generally requires twolevel Monte Carlo simulations. Given that the treatment effect only affects exacerbation rates, which has a linear relation with model outcomes, the inner loop of the EVPPI could be calculated analytically as described by Brennan et al. [17] and Jalal et al. [18] . Thus, we could calculate EVPPIs in a single-level simulation using the same 10,000 samples. Because the model outputs have perfectly linear relation to cost and utility parameters, EVPPI for costs and utilities could be calculated similarly. Population EVPI and EVPPIs, adjusted for time and population horizon of the decision context, sets an upper limit for the benefit of future studies that will generate evidence for the decision task [3] . In this work, we focused on individual EVPI and EVPPI, as converting them from individual level to population level is independent of the way the evidence on the effect size is generated, and would have no effect on the overall interpretation of our findings.
A future RCT might not necessarily incorporate all the interventions. The EVI outcomes can also be calculated for a situation that the investigator is interested in a future comparison of a subset of treatments. Accordingly, we calculated the EVI outcomes for all possible comparisons involving two or more treatments. We drew the maximum EVPI curve as a function of WTP for QALY. We created a rank table of comparisons based on EVPIs and EVPPIs and evaluated whether the ranking of comparisons remained consistent across the PMA-and NMA-based analyses. Table 2 shows the expected value of the model outcomes, as well as the ICER and the INMB (compared with placebo) for all treatments. Cost-effectiveness outcomes were generally the same across the two evidence-synthesis Fig. 2 Schematic representation of the COPD decision-analytic model. Two-sided arrows represent the possibility of going back and forth between states. One-sided arrows represent one-way transitions between states. All states have the potential of transitioning to death. COPD chronic obstructive pulmonary disease. This figure was re-used with permission from BiomedCentral. The original figure is found in Thorlund et al. [10] paradigms. For both PMA-and NMA-based analyses, ICS had the highest INMB, followed by LAMA. The similarity of the cost-effectiveness outcomes indicates that the direct evidence (used in both PMA and NMA) and the indirect evidence (used in NMA) are generally consistent, a finding that could be further corroborated by the comparison of direct and indirect RRs (Online Supplementary MaterialAppendix I).
Results
The maximum EVPI as a function of WTP for RCTs with all or a subset of the study treatments is provided in Fig. 3 for comparisons involving five (top left panel), four (top right panel), three (bottom left panel), and two (bottom right panel) treatments. For all panels in this figure, the comparison with the highest EVPI and its corresponding EVPI value are depicted for each value of WTP. For instance, at WTP of Can$50,000/QALY, the EVPI involving all five interventions was Can$1,262 for the PMA-based analysis and Can$572 for the NMA-based analysis (top left panel). In general, at any given WTP, the maximum EVPI for the PMAbased analysis was higher than its counterpart in the NMAbased analysis, an expected finding because the PMA-based analysis ignores the indirect evidence and hence overestimates the opportunity loss.
The ranking of EVPIs for each subset of comparisons are provided in Fig. 4a . Within each set of comparisons involving a similar number of treatments, the ranking is performed based on the results of the PMA-based analysis; therefore the bars on the left side progressively get larger within each set of similar-sized comparisons. The corresponding EVPIs for the NMA-based analysis are provided on the right side of the graph. As seen in this figure, there is substantial discrepancy in the ranking of EVPIs between the PMA-and NMA-based analyses. For four-, three-, and two-arm comparisons, the comparisons with the highest EVPI were different between the two methods. Additionally, the PMA-based EVPIs were larger than their NMA-based counterparts in all comparisons. A similar pattern was observed for EVPPIs associated with treatment effects (Fig. 4b) . For EVPPI for cost and utility parameters, there was again substantial difference in the magnitude of EVPPIs and ranking of comparisons. However, unlike EVPPIs for the effect sizes, the PMA-based EVPPIs for costs and utilities were not necessarily larger than their NMA-based counterparts (Supplementary Material Appendix-III).
Discussion
Our case study illustrates the impact of two evidencesynthesis paradigms, PMA as a conventional evidencesynthesis paradigm that only incorporates direct evidence, and NMA as a paradigm that includes the entire network of evidence, on EVI outputs of a decision-analytic model. The EVI estimates for treatment effect were generally larger when evidence synthesis was carried out using a PMA of placebo-based comparisons, in contrast with the NMA of the entire network of comparisons. This makes sense, as evidence synthesis using NMA includes more RCTs and therefore is based on higher quantities of information, concordantly resulting in lower estimates of opportunity loss because of uncertainty. If such EVI outcomes are used as a figure of merit to evaluate whether conducting future studies is justifiable, it might be the case that the NMAbased analysis will recommend no need for future studies, whereas a PMA-based analysis will indicate such studies are worth conducting (or suggest studies that are already Fig. 3 The maximum individual expected value of perfect information (EVPI) as a function of willingness-to-pay (WTP) for the future randomized controlled trial with all possible subset of interventions when the evidence on treatment effect is generated using a pairwise meta-analysis (PMA) or network meta-analysis (NMA). Only treatment comparisons with highest EVPI were plotted. ICS inhaled corticosteroids, LABA long-acting beta agonists, LAMA long-acting muscarinic agents undertaken but ignored in evidence synthesis). Further, rankings of comparisons based on their EVI outcomes vastly differed across the two evidence-synthesis paradigms. Thus, even if both NMA-and PMA-based analyses indicate that future research is potentially justifiable, they might result in different designs for future studies.
Although no overarching conclusions can be made from a single case study, our results confirmed our initial intuition that the use of evidence from indirect comparisons and the resulting change in the amount of uncertainty around the Previous authors have evaluated the impact of the evidence-synthesis paradigm on the outputs of economic evaluations [9] . Cooper et al. [9] have studied the value of using NMAs vs. PMAs in a sample of economic evaluations. They concluded that the NMA-based approach to evidence synthesis allows the evidence on clinical effectiveness to be treated as a coherent whole, include more data, and sometimes relaxes the assumptions made in the PMA. Our study extends such conclusions to the EVI context.
There were some limitations in our study. First and foremost, our results represent a single case study, and they should be interpreted accordingly. The overall finding that NMA-based EVI outcomes for treatment effect are smaller than their PMA counterparts will be reproducible in most realistic settings. However, there are instances in which the incorporation of the indirect evidence actually reduces the precision, thus potentially increasing EVI values; an example is when the overall between-study heterogeneity is increased with the inclusion of indirect evidence. We did not comprehensively evaluate all EVI metrics (such as the expected value of sample information) or EVPPIs for several other model parameters. The former is likely to follow the same pattern as the EVPI, and the latter is likely to have a complex and non-predictable association with the choice of evidence-synthesis paradigm, as our results on EVPPI for costs and utilities indicate; however, these remain to be empirically investigated. Our decision-analytic model of COPD might be considered simplistic. For example, recent evidence postulates that the occurrence of COPD exacerbation negatively affects the course of the disease, and as such, pharmacotherapies can indirectly affect the rate of progression [19] . Further, the treatment effects were estimated from the trials that for the most part followed participants for less than a year. Thus, we have made the strong assumption that the treatment effect will persist over the span of 10 years. Such concerns regarding the validity of the model, however, are separate from the conceptual developments, implementation of the methods, and implications of the results.
Given these results, a natural question that follows is: 'what form of evidence synthesis, PMA or NMA, is the preferred paradigm informing the research decision?' In addressing this question, we first note that both PMA and NMA are statistical models generating probability distributions for an outcome of interest from a set of data points. The validity of inference from both models hinges upon the suitability of the underlying assumptions in the given context. Compared with PMA, NMA provides inference on the joint distribution of effect sizes and therefore provides information on additional parameters pertaining to the covariance between outcomes. This has generated some misgivings as to the transferability of evidence across trials that have non-overlapping interventions [20, 21] . However, it has already been pointed out that in its core, NMA is an extension of PMA and therefore relies on the same core assumption of exchangeability (i.e., homogeneity) of treatment effects across trials [8] . In addition, in probabilistic decision analyses involving multiple strategies, making assumptions on such joint distributions is inevitable [22] . Overall, aside from the issue of model validity, we believe the principle of comprehensiveness in decision making is strongly in favor of the use of NMA in both the adoption and research decisions [4] . The principle underlying NMA is to use the entire network of evidence, instead of a series of pairwise comparisons, in a consistent statistical framework for evidence synthesis. While such networks have typically been constructed for the estimation of treatment effect, they can theoretically be expanded to jointly estimate the distribution of multiple parameters such as adverse events or the health state utility values. In addition, the Bayesian nature of NMA allows one to use informative priors to incorporate external information (e.g., expert opinion). All in all, NMA is a flexible statistical paradigm allowing efficient use of the available information to better inform both treatment and research decisions.
As the importance of comprehensiveness in formal evaluations of competing health technologies grows, so should the rigor of the analyses underlying such evaluations. Comprehensiveness and objectivity in synthesizing the evidence base is strongly emphasized [4, 23] . Quantitative methods of evidence synthesis that use the entire network of evidence offer conceptual and practical advantages over more traditional pairwise methods such as consistency and added precision. The methodology behind such forms of evidence synthesis is also actively being developed and the predicaments in the use of such methods (e.g., lack of familiarity of the analyst or the consumers of economic evaluations, lack of standardized and userfriendly software) are being addressed [24] . Although based on one case study, the present research provides empirical support that adopting this form of evidence synthesis can have important consequences in informing the 'research decision'.
